PATH stock closed at $10.70 on 02 Mar 2026 as investors digest UiPath Inc.’s AI positioning ahead of the March 11 earnings report. The New York listed company (UiPath, PATH, NYSE) traded 31,201,587 shares with a 52-week range of $9.38–$19.84. Valuation sits at PE 25.50 and market cap near $5.73 billion USD, while the 50-day average price is $14.08. Today’s price action reflects mixed signals: strong product momentum in agentic AI but nearby catalysts and analyst targets will drive volatility into the quarter.

PATH stock: Market snapshot and price action

UiPath (PATH) closed at $10.70 on the NYSE with volume 31,201,587 shares and a relative volume of 0.88. The stock opened at $10.41, hit a day low of $10.31 and a day high of $10.86. Short-term momentum has been negative: 50-day average is $14.08 and 200-day average is $13.48, showing recent weakness versus longer-term levels.

PATH stock: Fundamentals and valuation

UiPath reports trailing EPS of $0.42 and a trailing PE of 25.50, with revenue per share TTM of $2.88 and book value per share of $3.57. Cash per share is $2.59 and the company carries minimal net debt, supporting a healthy current ratio of 2.54. Price-to-sales is 3.71 and price-to-book is 3.01, indicating premium expectations for growth despite compressed share price.

PATH stock: AI strategy and product catalysts

UiPath’s push into agentic AI and recent healthcare tools are primary growth drivers that analysts cite for adoption and upsell. The company joined the Agentic AI Foundation and launched new AI automation for healthcare, which can expand enterprise use cases and contract value. Institutional activity, including a new Quantbot stake, reflects investor interest in the AI transition MarketBeat.

PATH stock: Technical setup and trading indicators

Technically, PATH carries RSI 35.75 and MACD slightly negative, showing near-term oversold conditions. Bollinger middle band sits at $11.43 and lower band at $9.53, giving a range for mean reversion. Average true range is $0.74, and ADX 34.70 indicates a strong trend, which currently favors downside pressure into earnings.

PATH stock: Analyst views, insider moves, and risks

Wall Street consensus is mixed: one Buy, ten Hold and a consensus price target near $15.77 per MarketBeat. Recent analyst target raises range from $12.00 to $19.00 reflect differing views on AI revenue lift. Insiders have sold into strength; CEO and CFO transactions reduced holdings, and insiders still own 23.19%. Key risks: competitive consolidation in AI (e.g., Anthropic deals), execution on agentic products, and long receivables days (~116.59 days). For price context see Reuters coverage Reuters.

PATH stock: Meyka grade and forecast

Meyka AI rates PATH with a score out of 100: 76.20 | Grade: B+ | Suggestion: BUY. This grade factors S&P 500 comparison, sector and industry performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year target of $15.48 USD, implying 44.63% upside from $10.70. Forecasts are model-based projections and not guarantees. For real-time metrics visit our Meyka page for PATH: https://meyka.ai/stocks/PATH.

Final Thoughts

UiPath (PATH, NYSE) trades at $10.70 USD as investors balance agentic AI progress against mixed analyst views and near-term execution risk. Fundamentals show cash strength and improving profitability (net margin 14.79% TTM) but valuation still prices growth, with PE 25.50 and price-to-sales 3.71. Recent product launches and the Agentic AI Foundation membership are positives that could lift enterprise adoption. However, headwinds include competitive consolidation and working-capital dynamics (DSO 116.59 days). Meyka AI’s forecast projects $15.48 in 12 months, an implied 44.63% upside versus the current price of $10.70 USD, while consensus targets cluster near $15.77. Traders should watch the March 11 earnings release and how UiPath ties AI features to contract expansion. Our analysis frames PATH stock as a growth-with-risk idea: attractive on selective buys for investors who accept volatility and can hold through product adoption cycles. Forecasts are model projections and not guarantees; conduct your own research before acting.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.